These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 20860038)

  • 1. Phase 1 trial and pharmacokinetic study of the farnesyl transferase inhibitor tipifarnib in children and adolescents with refractory leukemias: a report from the Children's Oncology Group.
    Widemann BC; Arceci RJ; Jayaprakash N; Fox E; Zannikos P; Goodspeed W; Goodwin A; Wright JJ; Blaney SM; Adamson PC; Balis FM
    Pediatr Blood Cancer; 2011 Feb; 56(2):226-33. PubMed ID: 20860038
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I trial and pharmacokinetic study of the farnesyltransferase inhibitor tipifarnib in children with refractory solid tumors or neurofibromatosis type I and plexiform neurofibromas.
    Widemann BC; Salzer WL; Arceci RJ; Blaney SM; Fox E; End D; Gillespie A; Whitcomb P; Palumbo JS; Pitney A; Jayaprakash N; Zannikos P; Balis FM
    J Clin Oncol; 2006 Jan; 24(3):507-16. PubMed ID: 16421428
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Phase 1 and pharmacokinetic clinical trial of paclitaxel for the treatment of refractory leukemia in children: a Children's Oncology Group study.
    Horton TM; Ames MM; Reid JM; Krailo MD; Pendergrass T; Mosher R; Reaman GH; Seibel NL;
    Pediatr Blood Cancer; 2008 Apr; 50(4):788-92. PubMed ID: 17668866
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase I trial and pharmacokinetic study of sorafenib in children with refractory solid tumors or leukemias: a Children's Oncology Group Phase I Consortium report.
    Widemann BC; Kim A; Fox E; Baruchel S; Adamson PC; Ingle AM; Glade Bender J; Burke M; Weigel B; Stempak D; Balis FM; Blaney SM
    Clin Cancer Res; 2012 Nov; 18(21):6011-22. PubMed ID: 22962440
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase I trial and pharmacokinetic study of tipifarnib, a farnesyltransferase inhibitor, and tamoxifen in metastatic breast cancer.
    Lebowitz PF; Eng-Wong J; Widemann BC; Balis FM; Jayaprakash N; Chow C; Clark G; Gantz SB; Venzon D; Zujewski J
    Clin Cancer Res; 2005 Feb; 11(3):1247-52. PubMed ID: 15709195
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase I clinical-pharmacodynamic study of the farnesyltransferase inhibitor tipifarnib in combination with the proteasome inhibitor bortezomib in advanced acute leukemias.
    Lancet JE; Duong VH; Winton EF; Stuart RK; Burton M; Zhang S; Cubitt C; Blaskovich MA; Wright JJ; Sebti S; Sullivan DM
    Clin Cancer Res; 2011 Mar; 17(5):1140-6. PubMed ID: 21233404
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I trial of tipifarnib in patients with recurrent malignant glioma taking enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study.
    Cloughesy TF; Kuhn J; Robins HI; Abrey L; Wen P; Fink K; Lieberman FS; Mehta M; Chang S; Yung A; DeAngelis L; Schiff D; Junck L; Groves M; Paquette S; Wright J; Lamborn K; Sebti SM; Prados M
    J Clin Oncol; 2005 Sep; 23(27):6647-56. PubMed ID: 16170172
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase I study of the farnesyltransferase inhibitor Tipifarnib in combination with the epidermal growth factor tyrosine kinase inhibitor Erlotinib in patients with advanced solid tumors.
    Jazieh K; Molina J; Allred J; Yin J; Reid J; Goetz M; Lim VS; Kaufmann SH; Adjei A
    Invest New Drugs; 2019 Apr; 37(2):307-314. PubMed ID: 30171497
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase 1 trial dose-escalation study of tipifarnib on a week-on, week-off schedule in relapsed, refractory or high-risk myeloid leukemia.
    Kirschbaum MH; Synold T; Stein AS; Tuscano J; Zain JM; Popplewell L; Karanes C; O'Donnell MR; Pulone B; Rincon A; Wright J; Frankel P; Forman SJ; Newman EM
    Leukemia; 2011 Oct; 25(10):1543-7. PubMed ID: 21625235
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase II study of the farnesyl transferase inhibitor, tipifarnib, in children with recurrent or progressive high-grade glioma, medulloblastoma/primitive neuroectodermal tumor, or brainstem glioma: a Children's Oncology Group study.
    Fouladi M; Nicholson HS; Zhou T; Laningham F; Helton KJ; Holmes E; Cohen K; Speights RA; Wright J; Pollack IF;
    Cancer; 2007 Dec; 110(11):2535-41. PubMed ID: 17932894
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I and pharmacokinetic study of farnesyl protein transferase inhibitor R115777 in advanced cancer.
    Zujewski J; Horak ID; Bol CJ; Woestenborghs R; Bowden C; End DW; Piotrovsky VK; Chiao J; Belly RT; Todd A; Kopp WC; Kohler DR; Chow C; Noone M; Hakim FT; Larkin G; Gress RE; Nussenblatt RB; Kremer AB; Cowan KH
    J Clin Oncol; 2000 Feb; 18(4):927-41. PubMed ID: 10673536
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I trial of tipifarnib in children with newly diagnosed intrinsic diffuse brainstem glioma.
    Haas-Kogan DA; Banerjee A; Kocak M; Prados MD; Geyer JR; Fouladi M; McKnight T; Poussaint TY; Broniscer A; Blaney SM; Boyett JM; Kun LE
    Neuro Oncol; 2008 Jun; 10(3):341-7. PubMed ID: 18417739
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase 1 study of the proteasome inhibitor bortezomib in pediatric patients with refractory leukemia: a Children's Oncology Group study.
    Horton TM; Pati D; Plon SE; Thompson PA; Bomgaars LR; Adamson PC; Ingle AM; Wright J; Brockman AH; Paton M; Blaney SM
    Clin Cancer Res; 2007 Mar; 13(5):1516-22. PubMed ID: 17332297
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I study of sorafenib and tipifarnib for recurrent glioblastoma: NABTC 05-02.
    Nghiemphu PL; Ebiana VA; Wen P; Gilbert M; Abrey LE; Lieberman F; DeAngelis LM; Robins HI; Yung WKA; Chang S; Drappatz J; Mehta MP; Levin VA; Aldape K; Dancey JE; Wright JJ; Prados M; Kuhn J; Cloughesy TF
    J Neurooncol; 2018 Jan; 136(1):79-86. PubMed ID: 28988377
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pediatric phase I trial and pharmacokinetic study of MLN8237, an investigational oral selective small-molecule inhibitor of Aurora kinase A: a Children's Oncology Group Phase I Consortium study.
    Mossé YP; Lipsitz E; Fox E; Teachey DT; Maris JM; Weigel B; Adamson PC; Ingle MA; Ahern CH; Blaney SM
    Clin Cancer Res; 2012 Nov; 18(21):6058-64. PubMed ID: 22988055
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase 1 dosing study of ruxolitinib in children with relapsed or refractory solid tumors, leukemias, or myeloproliferative neoplasms: A Children's Oncology Group phase 1 consortium study (ADVL1011).
    Loh ML; Tasian SK; Rabin KR; Brown P; Magoon D; Reid JM; Chen X; Ahern CH; Weigel BJ; Blaney SM
    Pediatr Blood Cancer; 2015 Oct; 62(10):1717-24. PubMed ID: 25976292
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I study of alternate-week administration of tipifarnib in patients with myelodysplastic syndrome.
    Kurzrock R; Kantarjian HM; Blascovich MA; Bucher C; Verstovsek S; Wright JJ; Pilat SR; Cortes JE; Estey EH; Giles FJ; Beran M; Sebti SM
    Clin Cancer Res; 2008 Jan; 14(2):509-14. PubMed ID: 18223226
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase 2 randomized, flexible crossover, double-blinded, placebo-controlled trial of the farnesyltransferase inhibitor tipifarnib in children and young adults with neurofibromatosis type 1 and progressive plexiform neurofibromas.
    Widemann BC; Dombi E; Gillespie A; Wolters PL; Belasco J; Goldman S; Korf BR; Solomon J; Martin S; Salzer W; Fox E; Patronas N; Kieran MW; Perentesis JP; Reddy A; Wright JJ; Kim A; Steinberg SM; Balis FM
    Neuro Oncol; 2014 May; 16(5):707-18. PubMed ID: 24500418
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II trial of tipifarnib plus neoadjuvant doxorubicin-cyclophosphamide in patients with clinical stage IIB-IIIC breast cancer.
    Sparano JA; Moulder S; Kazi A; Coppola D; Negassa A; Vahdat L; Li T; Pellegrino C; Fineberg S; Munster P; Malafa M; Lee D; Hoschander S; Hopkins U; Hershman D; Wright JJ; Kleer C; Merajver S; Sebti SM
    Clin Cancer Res; 2009 Apr; 15(8):2942-8. PubMed ID: 19351752
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase 1 study of cabozantinib in children and adolescents with recurrent or refractory solid tumors, including CNS tumors: Trial ADVL1211, a report from the Children's Oncology Group.
    Chuk MK; Widemann BC; Minard CG; Liu X; Kim A; Bernhardt MB; Kudgus RA; Reid JM; Voss SD; Blaney S; Fox E; Weigel BJ
    Pediatr Blood Cancer; 2018 Aug; 65(8):e27077. PubMed ID: 29693796
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.